|
No records
|
|
168 |
Andriyati R., Firman D., Kurniawati Y., Alkatiri A.A., Pranata R., Muliawan H.S., Rossimarina V., Soerianata S. |
57219712507;54898724100;57199153189;57210302708;57201973901;57203644653;57219708502;6504387197; |
Improved clinical outcome with biodegradable polymer drug-eluting stents compared to durable polymer drug-eluting stents for primary percutaneous coronary intervention |
2021 |
Postgraduate Medical Journal |
97 |
1152 |
|
638 |
643 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094912557&doi=10.1136%2fpostgradmedj-2020-138243&partnerID=40&md5=10b39bd26552fd6e6283165f7c0afe78 |
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia |
Andriyati, R., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Firman, D., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Kurniawati, Y., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Alkatiri, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Muliawan, H.S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Rossimarina, V., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Soerianata, S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia |
Background Studies comparing the clinical outcomes of second-generation biodegradable polymer drug-eluting stents (BP-DES) and second-generation durable polymer drug-eluting stents (DP-DES) in patients with ST-segment elevation myocardial infarction (STEMI) with follow-up duration of more than 1 year are still limited. Objective This study aimed to compare the 2-year clinical outcome of BP-DES with second-generation DP-DES in patients undergoing primary percutaneous coronary intervention (PPCI). Methods This is a retrospective cohort study in patients with STEMI, the primary endpoint was major adverse cardiac events (MACE) defined as recurrent myocardial infarction, total repeat revascularisation and cardiac death. The secondary endpoint was stent thrombosis (ST) defined as definite, probable or possible. Results A total of 400 patients were analysed (197 BP-DES groups and 203 DP-DES groups). BP-DES were independently associated with lower incidence of MACE (adjusted HR 0.67, 95% CI 0.21 to 0.91, p=0.005) and ST (adjusted HR 0.62, 95% CI 0.19 to 0.73, p<0.016) within 2 years of follow-up. Subgroup analysis of MACE individual components showed that BP-DES were associated with lower cardiac deaths (HR 0.35; 95% CI 0.18 to 0.94; p<0.001) compared to DP-DES, but not recurrent myocardial infarction and total repeat revascularisation. Conclusions BP-DES were associated with better clinical outcomes compared to second-generation DP-DES in patients with STEMI undergoing PPCI. © |
adult cardiology; Cardiology; coronary heart disease; coronary intervention; ischaemic heart disease; myocardial infarction |
acetylsalicylic acid; beta adrenergic receptor blocking agent; clopidogrel; creatinine; glucose; hydroxymethylglutaryl coenzyme A reductase inhibitor; ticagrelor; troponin I; troponin T; polymer; acute heart infarction; adult; Article; chronic kidney failure; clinical outcome; cohort analysis; controlled clinical trial; controlled study; coronary angiography; diabetes mellitus; diastolic blood pressure; dual antiplatelet therapy; dyslipidemia; female; fibrinolytic therapy; heart death; heart infarction; heart left ventricle ejection fraction; heart rate; human; hypertension; incidence; major adverse cardiac event; major clinical study; male; middle aged; mortality; non ST segment elevation myocardial infarction; observational study; percutaneous coronary intervention; retrospective study; |
BMJ Publishing Group |
00325473 |
|
32796116 |
Article |
Q2 |
568 |
8912 |
|
|
|
169 |
Anita N., Abinawanto, Jusuf A.A., Bowolaksono A., Saoemi H.A. |
57211777639;57285890300;57192275719;57205093224;57215011193; |
Effect of ethylene glycol on structural integrity at each stage of preantral follicle development post vitrification of rat ovary-histological analysis |
2021 |
HAYATI Journal of Biosciences |
28 |
4 |
|
304 |
311 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119020921&doi=10.4308%2fHJB.28.4.304-311&partnerID=40&md5=9e167a2dec7b6cf26ee525beea150963 |
Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia; Cellular and Molecular Mechanism in Biological System Research Group, Department of Biology, Universitas Indonesia, Depok, Indonesia; Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Master’s Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Anita, N., Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia, Cellular and Molecular Mechanism in Biological System Research Group, Department of Biology, Universitas Indonesia, Depok, Indonesia; Abinawanto, Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia; Jusuf, A.A., Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Bowolaksono, A., Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia; Saoemi, H.A., Master’s Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
The structure of follicular tissue affects the ability to maintain the structural integrity of follicles against cryoinjury post-vitrification. Histological analysis was conducted on the structural integrity of each stage of preantral follicles post-vitrification using 7.5% and 15.0% doses of ethylene glycol (EG), and ovarian sections with HE staining were observed using an Olympus CX21 microscope connected to Optilab 3.0 lens and Image Raster software. Analysis was conducted on the ovarian cortex in the tracing line area using polygon measure tools to obtain follicle density (follicles/mm2) and follicle index (%) data. The result showed that the EG group 7.5% (KP1) increased follicle density compared to the vitrified group (KKV) in primordial (15.83±1.77) and primary (22.94±8.51) stages. Meanwhile, KP2 (EG 15%) was in primordial (41.92±6.45), primary (11.69±1.95), secondary (33.48±3.63), and tertiary (5.93±0.69) stages. KP1 increased grade 3 follicle index compared to KKV in primary (27.66±2.34), secondary (32.41±6.99), and tertiary (25.00±5.00) stages. Meanwhile, KP2 was in primary (26.87±6.68) and tertiary (25.00±5.00) stages. Both doses of 7.5% and 15.0% EG were able to maintain structural integrity at certain stages of preantral follicles. Secondary and tertiary follicles are the best stages in maintaining grade 3 follicular integrity with the addition of 7.5% EG. ©2021 Institut Pertanian Bogor. |
Cryoinjury; Follicle density; Follicle index; Grading method; Preservation |
|
Bogor Agricultural University |
19783019 |
|
|
Article |
Q2 |
305 |
14644 |
|
|
|
170 |
Nainggolan G., Soemarko D., Siregar P., Sutranto A.L., Bardosono S., Prijanti A.R., Aulia D. |
23498775400;57192889490;57205715021;57286411000;21933841000;57190863386;6602865986; |
Diagnostic role of urine specific gravity to detect kidney impairment on heat-exposed workers in a shoe factory in Indonesia: A cross-sectional study |
2021 |
BMJ Open |
11 |
9 |
e047328 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116507527&doi=10.1136%2fbmjopen-2020-047328&partnerID=40&md5=b097275ffe1ee980cb242c3e4759fa0e |
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Division of Occupational Medicine, Department of Community Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Nutrition, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Clinical Pathology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Nainggolan, G., Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Soemarko, D., Division of Occupational Medicine, Department of Community Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Siregar, P., Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Sutranto, A.L., Division of Nephrology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Bardosono, S., Department of Nutrition, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Prijanti, A.R., Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Aulia, D., Department of Clinical Pathology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Objectives Globally, there are increasing cases of chronic kidney disease of unknown origin among heat-exposed workers. We aimed to see the kidney damages of indoor heat-exposed workers and whether urine specific gravity can predict any kidney damages. Design A cross-sectional study. Setting A shoe-making factory in West Java, Indonesia. Participants 119 subjects were included. Minimum total sample size was 62. Subjects were indoor heat-exposed workers who were exposed to occupational wet-bulb globe temperature (WBGT) of 28°C-30°C for 8 hours daily with 1 hour break, 5 days a week. The inclusion criterion was healthy subjects according to the result from annual medical check-up in 2019. The exclusion criteria were subjects who were taking vitamins and/or supplements that might cause disturbance in urine specific gravity and/or hydration status, pregnant and fasting. Primary and secondary outcome measures Area under the curve (AUC), sensitivity and specificity of urine specific gravity for the detection of urinary nephrin and urinary kidney injury molecule-1 (KIM-1) were analysed. Estimated glomerular filtration rate (eGFR) and quantitative albuminuria were also measured. Results WBGT in the work area of the subject was 28°C-30°C. There were 15 (12.6%) subjects who had eGFR <90 mL/min, but ≥60 mL/min. High serum vasopressin levels were found in 79 subjects with a mean of 6.54 (95% CI 5.94 to 7.14) ng/mL. Most subjects had nephrinuria (87.4%) with preserved renal function (87.4%). Several subjects had elevated urinary KIM-1 (10.9%) and albuminuria (7.6%). AUC of urine specific gravity for increased urinary nephrin was 81.7% (95% CI 68.8% to 94.6%) and statistically significant (p<0.001). Cut-off value of ≥1.018 for urine specific gravity has sensitivity of 71.2% and specificity of 80% for detecting elevation of urinary nephrin levels. Conclusion Urine specific gravity with a cut-off value of ≥1.018 could be used to detect nephrinuria among heat-exposed workers. © |
clinical chemistry; nephrology; occupational & industrial medicine |
albumin; hepatitis A virus cellular receptor 1; nephrin; vasopressin; adult; albumin blood level; albuminuria; Article; cross-sectional study; estimated glomerular filtration rate; factory worker; fasting; female; human; hydration status; Indonesia; kidney function; kidney injury; major clinical study; medical examination; nephrinuria; occupational exposure; pregnancy; proteinuria; relative density; sensitivity and specificity; shoe industry; thermal exposure; urine; urine level; urine sampling; vasopressin blood level; wet bulb globe temperature; wet bulb temperature; adverse event; chronic kidney failure; heat; heat injury; kidney; occupational exposure; relative density; Cross-Sectional Studies; Heat Stress Disorders; Hot Temperature; Humans; Indonesia; Kidney; Occupational Exposure; Re |
BMJ Publishing Group |
20446055 |
|
34588241 |
Article |
Q1 |
1132 |
3624 |
|
|
|
171 |
Pudjiadi A.H., Putri N.D., Sjakti H.A., Yanuarso P.B., Gunardi H., Roeslani R.D., Pasaribu A.D., Nurmalia L.D., Sambo C.M., Ugrasena I.D.G., Soeroso S., Firman A., Muryawan H., Setyanto D.B., Citraresmi E., Effendi J.A., Habibah L., Octaviantie P.D., Utami I.N.A., Prawira Y., Kaswandani N., Alam A., Kadafi K.T., Pulungan A.B. |
18435202300;57200573842;57195720458;57205428706;56510252700;57191512707;57287717900;57288262700;57287718000;57224730593;15133254800;57215582843;57287718100;57203009929;57224512641;57287899600;57287899700;57287718200;57287718300;55455747000;57195941745;57201672408;57211313656;57192905981; |
Pediatric COVID-19: Report From Indonesian Pediatric Society Data Registry |
2021 |
Frontiers in Pediatrics |
9 |
|
716898 |
|
|
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116558206&doi=10.3389%2ffped.2021.716898&partnerID=40&md5=8c294f39457ac77d477f3bb1d2dd9eb4 |
The Indonesian Pediatric Society, Jakarta, Indonesia; Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Department of Pediatrics, Faculty of Medicine, Dr. Soetomo Hospital, Universitas Airlangga, Surabaya, Indonesia; Department of Pediatrics, Faculty of Medicine, Hasan Sadikin Hospital, Universitas Padjajaran, Bandung, Indonesia; Department of Pediatrics, Faculty of Medicine, Dr. Kariadi Hospital, Universitas Diponegoro, Semarang, Indonesia; Department of Pediatrics, Harapan Kita Women and Children Hospital, Jakarta, Indonesia; Department of Pediatrics, Fatmawati Hospital, Jakarta, Indonesia; Department of Pediatrics, Faculty of Medicine, Dr. Saiful Anwar Hospital, Universitas Brawijaya, Malang, Indonesia |
Pudjiadi, A.H., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Putri, N.D., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Sjakti, H.A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Yanuarso, P.B., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Gunardi, H., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Roeslani, R.D., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Pasaribu, A.D., The Indonesian Pediatric Society, Jakarta, Indonesia; Nurmalia, L.D., The Indonesian Pediatric Society, Jakarta, Indonesia; Sambo, C.M., The Indonesian Pediatric Society, Jakarta, Indonesia; Ugrasena, I.D.G., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Dr. Soetomo Hospital, Universitas Airlangga, Surabaya, Indonesia; Soeroso, S., The Indonesian Pediatric Society, Jakarta, Indonesia; Firman, A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Hasan Sadikin Hospital, Universitas Padjajaran, Bandung, Indonesia; Muryawan, H., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Dr. Kariadi Hospital, Universitas Diponegoro, Semarang, Indonesia; Setyanto, D.B., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Citraresmi, E., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Harapan Kita Women and Children Hospital, Jakarta, Indonesia; Effendi, J.A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Fatmawati Hospital, Jakarta, Indonesia; Habibah, L., The Indonesian Pediatric Society, Jakarta, Indonesia; Octaviantie, P.D., Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Utami, I.N.A., The Indonesian Pediatric Society, Jakarta, Indonesia; Prawira, Y., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Kaswandani, N., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia; Alam, A., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Hasan Sadikin Hospital, Universitas Padjajaran, Bandung, Indonesia; Kadafi, K.T., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Dr. Saiful Anwar Hospital, Universitas Brawijaya, Malang, Indonesia; Pulungan, A.B., The Indonesian Pediatric Society, Jakarta, Indonesia, Department of Pediatrics, Faculty of Medicine, Cipto Mangunkusumo National Central Hospital, Universitas Indonesia, Jakarta, Indonesia |
Background: Indonesia has a high number of COVID-19 cases and mortalities relative to not only among the Asia Pacific region but the world. Children were thought to be less affected by the virus compared to adults. Most of the public data reported combined data between adults and children. The Indonesian Pediatric Society (IPS) was involved in the COVID-19 response, especially in the area of child health. One of IPS's activities is collecting data registries from each of their chapters to provide a better understanding of COVID-19 in children. Objective: The objective of this study was to share the data of suspected and confirmed COVID-19 cases in children from IPS's COVID-19 data registry. Method: This is a retrospective study from the IPS's COVID-19 registry data. We collected the data of COVID-19 in children during March to December 2020 from each of the IPS chapters. We analyzed the prevalence, case fatality rate (CFR), age groups, diagnosis, and comorbidities of the children diagnosed with COVID-19. Result: As of December 21, 2020, there were 35,506 suspected cases of children with COVID-19. In total, there were 522 deaths, with a case fatality ratio (CFR) of 1.4. There were 37,706 confirmed cases with 175 fatalities (CFR 0.46). The highest mortality in confirmed COVID-19 cases was from children ages 10–18 years (42 out of 159 cases: 26%). The most common comorbidity and diagnosis found were malignancy (17.3%) and respiratory failure (54.5%). Conclusion: The CFR of confirmed COVID-19 cases in children in Indonesia is high and should be a major public concern. © Copyright © 2021 Pudjiadi, Putri, Sjakti, Yanuarso, Gunardi, Roeslani, Pasaribu, Nurmalia, Sambo, Ugrasena, Soeroso, Firman, Muryawan, Setyanto, Citraresmi, Effendi, Habibah, Octaviantie, Utami, Prawira, Kaswandani, Alam, Kadafi and Pulungan. |
children; comorbidities; COVID-19; Indonesia; mortality |
adolescent; adult; Article; case fatality rate; cause of death; child; comorbidity; coronavirus disease 2019; human; Indonesia; major clinical study; malignant neoplasm; medical society; mortality; pediatrics; prevalence; questionnaire; register; respiratory failure; retrospective study; sepsis; septic shock |
Frontiers Media S.A. |
22962360 |
|
|
Article |
Q1 |
960 |
4641 |
|
|
|
172 |
Mustika S., Pratama M.Z., Lesmana C.R.A. |
37063469000;56993540600;8977683000; |
Diagnostic challenge in a patient presenting with ascites and hypergammaglobulinemia |
2021 |
Case Reports in Gastroenterology |
15 |
3 |
|
810 |
818 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116089151&doi=10.1159%2f000518384&partnerID=40&md5=abcdfe47d8eee85899e25c7644e30957 |
Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Mustika, S., Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Pratama, M.Z., Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Lesmana, C.R.A., Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Ascites is defined as the accumulation of intra-peritoneal fluid that can be caused by several diseases. We described a 47-year-old female presenting with low serum-ascites albumin gradient (SAAG) and a markedly high level of serum globulin. Serum protein electrophoresis revealed an M spike in the gamma region. Other laboratory results showed a marked increase in aspartate aminotransferase and alanine aminotransferase and predominantly conjugated hyperbilirubinemia without a sign of dilatation of bile ducts from abdominal ultrasonography examination. Furthermore, the follow-up showed a positive result for the anti-nuclear antibody test. The patient was assessed with autoimmune hepatitis, and the cause of ascites was suggested from portal hypertension although the level of SAAG was low. The ascites condition got improved after salt restriction, diuretics treatment, and abdominal paracentesis. However, the patient passed away because of the intracranial hemorrhage as a result of prolonged INR and APTT due to liver failure. © 2021 |
Ascites; Autoimmune hepatitis; Hypergammaglobulinemia |
alanine aminotransferase; albumin; alkaline phosphatase; antinuclear antibody; aspartate aminotransferase; bilirubin; creatinine; diuretic agent; furosemide; gamma glutamyltransferase; lactate dehydrogenase; prednisone; serum globulin; spironolactone; triacylglycerol; urobilinogen; ursodeoxycholic acid; abdominal circumference; activated partial thromboplastin time; adult,human; Article; ascites; autoimmune hepatitis; bile duct dilatation; body weight loss; bone marrow biopsy; brain hemorrhage; case report; echography; enzyme linked immunosorbent assay; female; follow up; gastrointestinal hemorrhage; human; human tissue; human,clinical article; hyperbilirubinemia; hypergammaglobulinemia; international normalized ratio; jaundice; leg swelling; leukocytosis; liver failure; liver function tes |
S. Karger AG |
16620631 |
|
|
Article |
Q3 |
247 |
16829 |
|
|
|
173 |
Forrat R., Dayan G.H., DiazGranados C.A., Bonaparte M., Laot T., Capeding M.R., Sanchez L., Coronel D.L., Reynales H., Chansinghakul D., Hadinegoro S.R.S., Perroud A.P., Frago C., Zambrano B., Machabert T., Wu Y., Luedtke A., Price B., Vigne C., Haney O., Savarino S.J., Bouckenooghe A., Noriega F. |
36339272700;6701860993;56721307400;56614799700;24471016000;6602161242;57201082261;56418742600;55343075300;29067671300;56893685800;57198777256;56255310300;7801355579;57201364463;57215829074;54395741500;57002517700;57192890936;57215866119;57220410062;18233281300;7005980306; |
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America |
2021 |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
73 |
6 |
|
1003 |
1012 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116958578&doi=10.1093%2fcid%2fciab288&partnerID=40&md5=cceec1a946e6b236b138dcb4bb663855 |
Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Clinical Sciences Sanofi PasteurPA, United States; Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Clinical Sciences, Sanofi PasteurMexico City, Mexico; Centro de Atencion e Investigación Médica, Bogotá, Colombia; Research & Development, Sanofi PasteurBangkok, Thailand; Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Clinical Sciences, Sanofi Pasteur, Singapore; Clinical Sciences, Sanofi Pasteur, Uruguay; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Global Pharmacovigilance, Sanofi PasteurPA, United States |
Forrat, R., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Dayan, G.H., Clinical Sciences Sanofi PasteurPA, United States; DiazGranados, C.A., Clinical Sciences Sanofi PasteurPA, United States; Bonaparte, M., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Laot, T., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Capeding, M.R., Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Sanchez, L., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Coronel, D.L., Clinical Sciences, Sanofi PasteurMexico City, Mexico; Reynales, H., Centro de Atencion e Investigación Médica, Bogotá, Colombia; Chansinghakul, D., Research & Development, Sanofi PasteurBangkok, Thailand; Hadinegoro, S.R.S., Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Perroud, A.P., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Frago, C., Clinical Sciences, Sanofi Pasteur, Singapore; Zambrano, B., Clinical Sciences, Sanofi Pasteur, Uruguay; Machabert, T., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Wu, Y., Clinical Sciences Sanofi PasteurPA, United States; Luedtke, A., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Price, B., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Vigne, C., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Haney, O., Global Pharmacovigilance, Sanofi PasteurPA, United States; Savarino, S.J., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Bouckenooghe, A., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Noriega, F., Clinical Sciences Sanofi PasteurPA, United States |
BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection. RESULTS: In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CONCLUSIONS: CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. |
CYD-TDV; dengue; serostatus; VCD |
dengue vaccine; live vaccine; vaccine; virus antibody; Asia; child; controlled study; dengue; Dengue virus; follow up; human; randomized controlled trial; severe dengue; South and Central America; Antibodies, Viral; Asia; Child; Dengue; Dengue Vaccines; Dengue Virus; Follow-Up Studies; Humans; Latin America; Severe Dengue; Vaccines, Attenuated; Vaccines, Combined |
NLM (Medline) |
15376591 |
|
33822015 |
Article |
Q1 |
3440 |
518 |
|
|
|
174 |
Ambari A.M., Setianto B., Santoso A., Radi B., Dwiputra B., Susilowati E., Tulrahmi F., Wind A., Cramer M.J.M., Doevendans P. |
57189576921;57192893995;36905206100;6603494019;57195383994;57200092387;57210209635;57265425700;7102305152;7004918581; |
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: The RamiRHeD trial protocol |
2021 |
BMJ Open |
11 |
9 |
e048016 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115217044&doi=10.1136%2fbmjopen-2020-048016&partnerID=40&md5=37438fc881ccc33516a8361ba43e3971 |
Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Central Military Hospital, Netherlands Heart Institute, Utrecht, Netherlands |
Ambari, A.M., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Setianto, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Santoso, A., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Radi, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Dwiputra, B., Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, West Jakarta Jakarta, Indonesia; Susilowati, E., Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Tulrahmi, F., Research Assistant of Department of Cardiovascular Prevention and Rehabilitation, National Cardiovascular Center Harapan Kita, West Jakarta Jakarta, Indonesia; Wind, A., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Cramer, M.J.M., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands; Doevendans, P., Department of Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, Central Military Hospital, Netherlands Heart Institute, Utrecht, Netherlands |
Introduction Rheumatic heart disease (RHD) is a major burden in developing countries and accounts for 80% of all people living with the disease, where it causes most cardiovascular morbidity and mortality in children and young adults. Chronic inflammation and fibrosis of heart valve tissue due to chronic inflammation in RHD will cause calcification and thickening of the impacted heart valves, especially the mitral valve. This fibrogenesis is enhanced by the production of angiotensin II by increased transforming growth factor β expression and later by the binding of interleukin-33, which is known to have antihypertrophic and antifibrotic effects, to soluble sST2. sST2 binding to this non-natural ligand worsens fibrosis. Therefore, we hypothesise that ACE inhibitors (ACEIs) would improve rheumatic mitral valve stenosis. Methods and analysis This is a single-centre, double-blind, placebo-controlled, randomised clinical trial with a pre-post test design. Patients with rheumatic mitral stenosis and valve dysfunction will be planned for cardiac valve replacement operation and will be given ramipril 5 mg or placebo for a minimum of 12 weeks before the surgery. The expression of ST2 in the mitral valve is considered to be representative of cardiac fibrosis. Mitral valve tissue will be stained by immunohistochemistry to ST2. Plasma ST2 will be measured by ELISA. This study is conducted in the Department of Cardiology and Vascular Medicine, Universitas Indonesia, National Cardiac Center Harapan Kita Hospital, Jakarta, Indonesia, starting on 27 June 2019. Ethics and dissemination The performance and dissemination of this study were approved by the ethics committee of National Cardiovascular Center Harapan Kita with ethical code LB.02.01/VII/286/KEP.009/2018. Trial registration number NCT03991910. © 2021 BMJ Publishing Group. All rights reserved. |
cardiology; cardiothoracic surgery; valvular heart disease |
interleukin 1 receptor like 1 protein; placebo; ramipril; ramipril; adult; Article; clinical trial protocol; controlled study; double blind procedure; enzyme linked immunosorbent assay; female; heart muscle fibrosis; human; human tissue; immunohistochemistry; Indonesia; male; mitral valve stenosis; pretest posttest design; protein blood level; protein expression; randomized controlled trial; rheumatic heart disease; child; fibrosis; heart surgery; mitral valve stenosis; randomized controlled trial (topic); young adult; Cardiac Surgical Procedures; Child; Fibrosis; Humans; Mitral Valve Stenosis; Ramipril; Randomized Controlled Trials as Topic; Rheumatic Heart Disease; Young Adult |
BMJ Publishing Group |
20446055 |
|
34518254 |
Article |
Q1 |
1132 |
3624 |
|
|
|
175 |
Tamba R.P., Moenadjat Y. |
47761736600;57190371576; |
Oral Spermine Supplementation in Gestated Rabbit: A Study on Villi Height of Immature Intestines |
2021 |
Frontiers in Surgery |
8 |
|
721560 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115713070&doi=10.3389%2ffsurg.2021.721560&partnerID=40&md5=ef2b810fab926ddb3b4313b8d20045f5 |
Faculty of Medicine, Department of Surgery Cipto, Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia |
Tamba, R.P., Faculty of Medicine, Department of Surgery Cipto, Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia; Moenadjat, Y., Faculty of Medicine, Department of Surgery Cipto, Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia |
Introduction: Immature intestines are the major problem in prematurity. Postnatal oral spermine has been shown in studies to improve intestinal maturation in rats and piglets. This study aimed to find out the efficacy of spermine in rabbits during gestation. Method: An experimental study was done in an unblinded, randomized manner on those treated with and without spermine administration. A morphological examination of hematoxylin–eosin-stained villi was performed under a light microscope with a focus on villi height. Data were subjected to analysis. Results: The median of the spermine-treated group was found to be higher at 24, 26, and 28 days than the non-spermine group, but was not significantly different. Conclusion: Oral spermine supplementation during gestation might improve intestinal villi height in immature rabbit intestines. © Copyright © 2021 Tamba and Moenadjat. |
gestation; immature intestines; rabbit; spermine; villi height |
|
Frontiers Media S.A. |
2296875X |
|
|
Article |
Q2 |
483 |
10376 |
|
|
|
177 |
Karina K., Ekaputri K., Albert Biben J., Rosadi I., Rosliana I., Sobariah S., Sulaeha A.D., Andrew H., Afini I., Widyastuti T., Jusryanti J., Prestiani S.I., Donna I.M., Mutiara M.S., Habibi H. |
57212146678;57285088000;57284643500;57204720098;57186671400;57203547382;57226286645;57226282534;57211068324;57211074403;57284643600;57283770100;57284210300;57284210400;57222314524; |
Evaluation of plasma pdgf and vegf levels after systemic administration of activated autologous platelet-rich plasma |
2021 |
Biomedicine (India) |
41 |
|
|
409 |
412 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116318936&doi=10.51248%2f.v41i2.1047&partnerID=40&md5=b63a888f3eb59bb12b87fdd1bfa4f091 |
Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Faculty of Medicine, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia; Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, 752424, Indonesia; Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya no. 6, Jakarta Pusat, 10430, Indonesia |
Karina, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Faculty of Medicine, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia, Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia; Ekaputri, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Albert Biben, J., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Rosadi, I., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, 752424, Indonesia; Rosliana, I., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Sobariah, S., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Sulaeha, A.D., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Andrew, H., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya no. 6, Jakarta Pusat, 10430, Indonesia; Afini, I., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Widyastuti, T., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Jusryanti, J., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Prestiani, S.I., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Donna, I.M., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Mutiara, M.S., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Habibi, H., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia |
Introduction and Aim: Activated autologous platelet-rich plasma (aaPRP) is becoming a popular therapy to accelerate healing in the field of plastic surgery. Platelets, which are abundant in aaPRP, can release many growth factors including platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). This study aims to examine the plasma levels of PDGF and VEGF in healthy subjects after intravenous administration of aaPRP. Materials and Methods: Nine healthy patients with no prior history of metabolic disease were divided into two groups (control and experiment group). The treatment group which consists of six patients received intravenous aaPRP treatment. The preparation of aaPRP starts with the collection of 24 mL of whole blood in sodium citrate tubes followed a two-step centrifugation procedure and subsequent chemical activation. aaPRP was then administered intravenously to patients. Meanwhile, the control group received no intervention. Venous blood samples were taken before and one week after the treatment and the plasma PDGF and VEGF levels were determined by enzyme-linked immunosorbent assay (ELISA). Results: The treatment group showed statistically significant increase in VEGF after 7 days compared to before aaPRP administration. However, the change in PDGF levels of the treatment group was unnotable. Conclusion: The present findings indicate that intravenous administrations of activated aaPRP may increase plasma VEGF level up to 1 week after aaPRP administration. © 2021, Indian Association of Biomedical Scientists. All rights reserved. |
Activated autologous platelet-rich plasma (aaPRP); Platelet derived growth factor (PDGF); Vascular endothelial growth factor (VEGF) |
activated autologous platelet rich plasma; citrate sodium; platelet derived growth factor; thrombocyte concentrate; unclassified drug; vasculotropin; adult; Article; blood autotransfusion; blood chemistry; blood sampling; case control study; centrifugation; cohort analysis; controlled study; enzyme linked immunosorbent assay; female; human; human cell; male; metabolic disorder; middle aged; observational study; prospective study; protein blood level; thrombocyte rich plasma; venous blood |
Indian Association of Biomedical Scientists |
09702067 |
|
|
Article |
Q4 |
106 |
29384 |
|
|
|
178 |
Yamada C., Siste K., Hanafi E., Ophinni Y., Beatrice E., Rafelia V., Alison P., Limawan A., Shinozaki T., Matsumoto T., Sakamoto R. |
57222342981;55644113100;56737010600;57198779809;57215769595;57253865100;57254672000;57202712511;55129157400;55624483618;23992806400; |
Relapse prevention group therapy via video-conferencing for substance use disorder: Protocol for a multicentre randomised controlled trial in Indonesia |
2021 |
BMJ Open |
11 |
9 |
e050259 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114681155&doi=10.1136%2fbmjopen-2021-050259&partnerID=40&md5=f40f8485b5314829dcd4365ab57bf817 |
Department of Environmental Coexistence, Center for Southeast Asian Studies, Kyoto University, Kyoto, Japan; Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ragon Institute of Mgh, Mit and Harvard, Cambridge, MA, United States; Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan; Department of Drug Dependence Research, National Center of Neurology and Psychiatry, Tokyo, Japan |
Yamada, C., Department of Environmental Coexistence, Center for Southeast Asian Studies, Kyoto University, Kyoto, Japan; Siste, K., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Hanafi, E., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ophinni, Y., Ragon Institute of Mgh, Mit and Harvard, Cambridge, MA, United States; Beatrice, E., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rafelia, V., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Alison, P., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Limawan, A., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Shinozaki, T., Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan; Matsumoto, T., Department of Drug Dependence Research, National Center of Neurology and Psychiatry, Tokyo, Japan; Sakamoto, R., Department of Environmental Coexistence, Center for Southeast Asian Studies, Kyoto University, Kyoto, Japan |
Background Substance use disorder (SUD) is a leading contributor to the global burden of disease. In Indonesia, the availability of formal treatment for SUD falls short of the targeted coverage. A standardised therapeutic option for SUD with potential for widespread implementation is required, yet evidence-based data in the country are scarce. In this study, we developed a cognitive behavioural therapy (CBT)-based group telemedicine model and will investigate effectiveness and implementability in a multicentre randomised controlled trial. Methods A total of 220 participants will be recruited from the social networks of eight sites in Indonesia: three hospitals, two primary healthcare centres and three rehabilitation centres. The intervention arm will participate in a relapse prevention programme called the Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP), a newly developed 12-week module based on CBT and motivational interviewing constructed in the Indonesian context. The programme will be delivered by a healthcare provider and a peer counsellor in a group therapy setting via video-conferencing, as a supplement to participants' usual treatments. The control arm will continue treatment as usual. The primary outcome will be the percentage increase in days of abstinence from the primarily used substance in the past 28 days. Secondary outcomes will include addiction severity, quality of life, motivation to change, psychiatric symptoms, cognitive function, coping, and internalised stigma. Assessments will be performed at baseline (week 0), post-treatment (week 13), and 3 and 12 months post-treatment completion (weeks 24 and 60). Retention, participant satisfaction, and cost-effectiveness will be assessed as the implementation outcomes. Ethics and dissemination The study protocol was reviewed and approved by the Ethics Committees of Universitas Indonesia and Kyoto University. The results will be disseminated via academic journals and international conferences. Depending on trial outcomes, the treatment programme will be advocated for adoption as a formal healthcare-based approach for SUD. Trial registration number UMIN000042186. © 2021 BMJ Publishing Group. All rights reserved. |
clinical trials; psychiatry; substance misuse; telemedicine |
Article; benzodiazepine dependence; cannabis addiction; cognition; cognitive behavioral therapy; controlled study; coping behavior; cost effectiveness analysis; counselor; disease severity; drug dependence; drug withdrawal; group therapy; health care personnel; heroin dependence; human; Indonesia; major clinical study; mental disease; methamphetamine dependence; motivational interviewing; multicenter study; opiate addiction; outcome assessment; patient satisfaction; preventive health service; program effectiveness; quality of life; randomized controlled trial; relapse; stigma; teleconference; videoconferencing; cost benefit analysis; multicenter study (topic); randomized controlled trial (topic); secondary prevention; Cost-Benefit Analysis; Humans; Indonesia; Multicenter Studies as Topic; |
BMJ Publishing Group |
20446055 |
|
34489288 |
Article |
Q1 |
1132 |
3624 |
|
|
